A therapy that resets cellular age has graduated from theory to human trials, offering the ability to cure hundreds of diseases and reverse aging itself. Altos Labs has emerged as the dominant force translating this science into capital and credibility. Embryos naturally shed the epigenetic damage carried from parents, returning to a youthful baseline within weeks, and researchers have now learned to trigger this reset deliberately outside the womb.

Decades of tinkering with longevity genes have matured into a $20 trillion global market crowded with supplements, peptides and unproven biohacks. Backed by Jeff Bezos and Yuri Milner, Altos Labs launched in 2022 with $3 billion, luring top academics with million-dollar salaries while operating as a near-impenetrable research fortress. Juan Carlos Izpisua Belmonte previously extended mouse lifespans by 30 percent using partial epigenetic reprogramming.

Human safety studies began this March, targeting glaucoma and eye disease as the first proof that aged tissues can be restored without catastrophe. Izpisua Belmonte manipulates epigenetic markers that drift with stress, sun and time, misdirecting cells until organs falter. Virtual-cell artificial intelligence and organoid experiments now let scientists run bolder tests without crossing ethical red lines. Success would convert rejuvenation from spectacle into standard medical practice.